GGrantIndex
← Search

Pathology Resource Network

$509,588P30FY2011CANIH

Roswell Park Cancer Institute Corp, Buffalo NY

Investigators

Linked publications, trials & patents

Trial NCT07082270Trial NCT06202066Trial NCT05589844Trial NCT05338905Trial NCT05292521Trial NCT05231122Trial NCT04607291Trial NCT04533542Trial NCT04530812Trial NCT04526587Trial NCT04379518Trial NCT04358315Trial NCT04348747Trial NCT04298606Trial NCT04290962Trial NCT04269213Trial NCT04231539Trial NCT04207190Trial NCT04119830Trial NCT04110249Trial NCT04109924Trial NCT04093323Trial NCT04081389Trial NCT04073745Trial NCT04068649Trial NCT04067830Trial NCT04060446Trial NCT04032418Trial NCT04000581Trial NCT03965234Trial NCT03935347Trial NCT03899987Trial NCT03897270Trial NCT03895918Trial NCT03881735Trial NCT03880422Trial NCT03879694Trial NCT03865472Trial NCT03851081Trial NCT03793907Trial NCT03789877Trial NCT03751449Trial NCT03751436Trial NCT03736720Trial NCT03735589Trial NCT03735095Trial NCT03727789Trial NCT03727061Trial NCT03709550Trial NCT03691376Trial NCT03688945Trial NCT03685695Trial NCT03683147Trial NCT03680235Trial NCT03679585Trial NCT03679559Trial NCT03678350Trial NCT03630601Trial NCT03574792Trial NCT03457142Trial NCT03403634Trial NCT03384836Trial NCT03358719Trial NCT03348748Trial NCT03333486Trial NCT03297489Trial NCT03211416Trial NCT03206047Trial NCT03192397Trial NCT03090412Trial NCT03017131Trial NCT03011736Trial NCT02965976Trial NCT02955290Trial NCT02953457Trial NCT02947386Trial NCT02877641Trial NCT02857374Trial NCT02853318Trial NCT02833506Trial NCT02713373Trial NCT02650986Trial NCT02575885Trial NCT02575508Trial NCT02531906Trial NCT02474095Trial NCT02455557Trial NCT02452463Trial NCT02414724Trial NCT02399215Trial NCT02393755Trial NCT02334865Trial NCT02287727Trial NCT02227940Trial NCT02170389Trial NCT02166905Trial NCT02159950Trial NCT02119728Trial NCT02100254Trial NCT02072486

Abstract

The Pathology Resource Network (previously Translational Research Tissue Support Resource) incorporates three functions, Tissue Procurement, Paraffin Archive and Leukemia Tissue Bank under the supervision of Carl Morrison, MD, DVM, Director of the Division of Molecular Pathology, Department of Pathology &Laboratory Medicine. Dr Morrison was recruited from The Ohio State University in January 2007. He has been responsible for reorganizing the Resource to meet Institute and CCSG requirements. This resource provides human specimens for basic and translational research to further the understanding of the cellular and molecular pathogenesis of human cancers. The overall goal is to facilitate access to human tissue for IRB-approved investigators with an emphasis on translational efforts. Tissue Procurement serves the traditional role of providing anonymous fresh and frozen tissue to investigators requiring unfixed human tissue. There are two major changes: (1) Tissue Procurement is making the necessary changes to transform a majority of requests to a macromolecule delivery (DMA, RNA, protein), allowing for a more efficient use of these precious materials by other CCSG Resources such as Microarray and Genomics and allowing multiple investigators to utilize a single specimen;(2) a procurement mechanism is being established to allow for special collections of tissues with an emphasis on translational research. The Paraffin Archive is a repository of organ-specific neoplastic and non-neoplastic formalinfixed, paraffin-embedded clinical specimens. There are two major changes: (1) the hiring of dedicated personnel under the supervision of Dr Morrison;(2) an intense effort to organize these specimens into a translational theme utilizing tissue microarrays. The Pathology Core Facility serves as a research specimen processing laboratory and performs functions for individual investigators and for Tissue Procurement and Paraffin Archive ranging from basic histology and immunohistochemistry to processing specimens for macromolecules for Tissue Procurement and building tissue microarrays for the Paraffin Archive. The Leukemia Tissue Bank processes and cryopreserves cell samples from patients with hematological disorders for analysis of a variety of molecular pathogenetic and prognostic characteristics. This highly-integrated Resource with well controlled and characterized specimens will continue to serve as an important resource for enhancing translational research and collaborative efforts that will result in increased peer-reviewed funding and publication. The Resource is used by all six Programs and 96% of users are CCSG members. $221,883 in CCSG support is requested, representing 19% of the total operating budget.

View original record on NIH RePORTER →